Welcome To Burzynski Research Institute
Burzynski Research Institute (BRI), a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and developmental efforts are focused on cancer treatment with four pipeline drugs—antineoplastons (ANP) in 1 Phase III clinical trial and 14 Phase II clinical trials, some of which are ready to enter Phase III. The ultimate goal of the BRI is to discover, develop, and obtain the FDA’s marketing approval of ANP for the treatment of currently incurable types of cancer with emphasis on malignant brain tumors in adults and children.
.jpg)
Based on research sponsored by BRI, ANP affect approximately 100 human genes that are instrumental in the growth of highly-malignant tumors such as glioblastoma multiforme—the most common and uniformly deadly type of brain tumor. The results of our research with ANP are presented at a number of oncology and neuro-oncology meetings, and published in reputable medical journals.
|
